Internal Medicine, Endocrinology, Diabetes, & Metabolism · Rancho Mirage, CA
NPI
1891786729
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
1
Hospital affiliations
39000 Bob Hope Dr, K208
Rancho Mirage, CA, 92270
Phone (760) 773-5350
Medicare paid, 2024
$96K
894 services
Medicare patients, 2024
488
Average age 74
Drug cost, 2024
$1.5M
4,736 prescriptions
Company payments, 2025
$673
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohamad K Alnabelsi was code 99214 (office e&m - established), 434 times for 270 patients. In total Mohamad K Alnabelsi billed 894 services in 7 codes, and Medicare paid $96K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-06-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 434 | 270 | $98.97 | $43K |
| 99443 Telephone Services | Office | 314 | 235 | $99.18 | $31K |
| 99205 Office E&M - New | Office | 97 | 97 | $164.50 | $16K |
By year: 2022 $148K for 1,462 services; 2023 $130K for 1,289 services; 2024 $96K for 894 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohamad K Alnabelsi prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,049 prescriptions and refills. In total Mohamad K Alnabelsi wrote 4,736 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,049 | 2,850 | 265 | $12K |
| Glipizide Generic | 372 | 1,001 | 134 | $5,654 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 317 | 522 | 82 | $66K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 294 | 501 | 75 | $218K |
| Metformin Hcl Generic | 255 | 709 | 83 | $2,550 |
| Synthroid Levothyroxine Sodium | 202 | 555 | 54 | $18K |
| Ozempic Semaglutide | 186 | 327 | 51 | $291K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 164 | 418 | 77 | $26K |
| Trulicity Dulaglutide | 142 | 235 | 38 | $225K |
| Humalog Kwikpen U-100 Insulin Lispro | 137 | 271 | 45 | $37K |
| Glimepiride Generic | 129 | 380 | 43 | $2,151 |
| Methimazole Generic | 122 | 327 | 43 | $2,602 |
| Hydrocortisone Generic | 120 | 286 | 23 | $5,013 |
| Acarbose Generic | 116 | 335 | 44 | $6,590 |
| Jardiance Empagliflozin | 99 | 276 | 33 | $156K |
Brand drugs: 2,169 claims; generic drugs: 2,119 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohamad K Alnabelsi $673 ($673 in general payments such as food, travel and fees) from 10 companies. The largest payer was Amgen Inc. with $219.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 10 | $219 |
| Novo Nordisk Inc NVO | 12 | $175 |
| Lilly USA, LLC LLY | 2 | $64.17 |
| CeQur Corporation | 1 | $62.45 |
| Dexcom, Inc. DXCM | 1 | $40.2 |
| Ascendis Pharma Endocrinology Inc ASND | 1 | $27.57 |
| Corcept Therapeutics CORT | 1 | $24.13 |
| Xeris Pharmaceuticals, Inc. | 1 | $21.35 |
| Abbott Laboratories ABT | 1 | $20.98 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $18.54 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.